Penumbra (NYSE:PEN) announced additional results from its STORM-PE trial of computer-assisted vacuum thrombectomy (CAVT).
Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, ...
Investor's Business Daily on MSN
Penumbra Shoots For A Breakout On 'Another Impressive Quarter'
Penumbra stock skyrocketed Thursday after the medtech company beat third-quarter expectations on the back of its ...
STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the ...
Penumbra reported positive data for a trial of its treatment for pulmonary embolism. The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min At Penumbra Inc. Shruthi Narayan ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% ...
Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif., Sept. 9, 2025 /PRNewswire/ -- The American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback